A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
A phase 2 trial of Fruquintinib, Trifluridine/tipiracil in colorectal cancer, run by Criterium, Inc., now recruiting.
Overview
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06992258 by Criterium, Inc., with 120 participants planned, started 2025-10-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialInjection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
Shares Trifluridine/tipiracil, Fruquintinib, Colorectal cancer.
- TrialA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Shares Fruquintinib, Colorectal cancer.
- TrialA Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialTATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Shares Trifluridine/tipiracil, Fruquintinib.
- TrialNelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Shares Fruquintinib, Colorectal cancer.
- TrialSUNLIGHT
Shares Trifluridine/tipiracil, Colorectal cancer.